Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 11/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022515 | 0.87 | CA1 (0.45) | CA1CA2GRIA4 | |
| SCHEMBL4714206 | 0.86 | CA1 (0.44) | CA1CA2GRIA4KMT2AHTT | |
| SCHEMBL4714033 | 0.83 | CA1 (0.48) | CA1CA2GRIA4KMT2AHTT | |
| SCHEMBL4717985 | 0.82 | CA1 (0.47) | CA1CA2GRIA4KMT2AHTT | |
| SCHEMBL4711948 | 0.79 | CA1 (0.38) | CA1CA2GRIA4 | |
| SCHEMBL4712382 | 0.73 | CCR1 (0.41) | KMT2AHTTMEN1 | |
| SCHEMBL4017618 | 0.73 | HTT (0.37) | CA1CA2KMT2AHTTSMN1; SMN2 | |
| SCHEMBL4711944 | 0.73 | CA1 (0.37) | CA1CA2GRIA4 | |
| SCHEMBL4018016 | 0.73 | PTGES (0.37) | KMT2AHTTMEN1TSHRALDH1A1 | |
| SCHEMBL4716481 | 0.71 | NR1D1 (0.38) | KMT2AMEN1ALDH1A1IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | LABORATOIRES SERONO SA (CH) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | STS, TST, SULT1A1 | CA1 3624/4885CA2 2902/4885GRIA4 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.